Exploring factors that predict treatment response in patients with polymyalgia rheumatica and giant cell arteritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify predictive factors for how patients with newly diagnosed polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) respond to steroid treatment. It will evaluate the relationship between endogenous glucocorticoid suppression and the effectiveness of glucocorticoids in managing these conditions. By analyzing various biological markers and treatment responses, the study seeks to develop profiles for steroid responders and non-responders, which could inform treatment strategies. The ultimate goal is to optimize steroid use and minimize adverse effects for patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with diagnosis of PMR according to the 2012 provisional classification criteria and GCA according to published criteria
* Consent to participate in the SCQM database
* Treatment according to our standardized regimes

Exclusion Criteria:

* Treatment with Tocilizumab, MTX or other disease modifying medications at inclusion
* History of GCA and PMR in the past
* Inability to give informed consent

Where it's running

• Department of Rheumatology University Hospital Basel
  Basel, Switzerland Recruiting

Study contacts

• Principal investigator: Thomas Daikeler, Prof. Dr. med. — Department of Rheumatology University Hospital Basel
• Study coordinator: Thomas Daikeler, Prof. Dr. med.
• Email: Thomas.Daikeler@usb.ch
• Phone: +41 61 265 27 09

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized lab test to predict the best treatment for rheumatic diseases

  This project tests a lab-based cell assay to see if it can predict which DMARD will work best for adults with autoimmune rheumatic diseases such as RA, PsA, axSpA, and GCA.

  Recruiting University of Bonn · Bonn, North Rhine-Westphalia · NCT07150000

• Investigating the Role of Y Chromosome Mutations in Autoimmune Diseases

  This study is trying to see how changes in the Y chromosome might affect the immune system and contribute to autoimmune diseases like Giant Cell Arteritis and Polymyalgia Rheumatica.

  Recruiting University of Bonn · Bonn, North Rhine-Westphalia · NCT06696027

• Evaluating Thrombomodulin for Ruling Out Giant Cell Arteritis in Patients with Polymyalgia Rheumatica

  This study is testing if a blood marker called thrombomodulin can help doctors tell if older patients with polymyalgia rheumatica also have giant cell arteritis.

  Recruiting Centre Hospitalier Universitaire Dijon · Dijon · NCT06609668

• Hydrocortisone vs. placebo for adrenal insufficiency symptoms after stopping glucocorticoids

  This study is testing if hydrocortisone can help people over 50 feel better after stopping glucocorticoids and dealing with adrenal insufficiency symptoms.

  Recruiting at 3 sites Phase 4 Odense University Hospital · Aarhus and 2 other locations · NCT05193396

• Personalized Movement Training to Help People with PMR Move Better

  We’re testing whether a personalized Movement Pattern Training program can help people with polymyalgia rheumatica move more easily and reduce pain.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07749547

• Giant Cell Arteritis: Monitoring Disease Activity and Relapse Risk in Remission

  This study tests tools that help monitor disease activity and predict relapses in people with giant cell arteritis who are in remission.

  Recruiting at 4 sites University of Aarhus · Aalborg and 6 other locations · NCT07552636

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.